Penserra Capital Management LLC Caribou Biosciences, Inc. Transaction History

Penserra Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$4.08 - $8.14 $26,728 - $53,325	-6,551 Reduced 25.97%	18,672 $89,000
Q2 2023 Aug 11, 2023	BUY	$4.04 - $5.47 $25,585 - $34,641	6,333 Added 33.53%	25,223 $107,000
Q1 2023 Apr 24, 2023	BUY	$4.3 - $7.78 $21,027 - $38,044	4,890 Added 34.93%	18,890 $100,000
Q4 2022 Feb 13, 2023	SELL	$5.57 - $11.01 $55,627 - $109,956	-9,987 Reduced 41.64%	14,000 $87,000
Q3 2022 Nov 14, 2022	BUY	$5.34 - $12.79 $99,895 - $239,262	18,707 Added 354.3%	23,987 $253,000
Q2 2022 Aug 15, 2022	SELL	$5.1 - $9.74 $7,078 - $13,519	-1,388 Reduced 20.82%	5,280 $28,000
Q1 2022 May 13, 2022	BUY	$8.42 - $15.32 $56,144 - $102,153	6,668 New	6,668 $61,000

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $123M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.